Literature DB >> 1343768

Thyroid-associated ophthalmopathy.

A P Weetman1.   

Abstract

Thyroid-associated ophthalmopathy (TAO) is one of the most vexing problems in endocrinology but its relationship to thyroid autoimmunity is becoming more clear with the realisation that almost all patients with Graves' disease have this condition and almost all patients with ophthalmopathy have some form of thyroid involvement. This suggests cross reactivity between thyroid and retrobulbar antigens, of which one potential candidate has recently been cloned. Together with new information on predisposing factors and the important role of the retrobulbar fibroblasts, these developments shed new light on the aetiology and pathogenesis of this enigmatic disorder.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1343768     DOI: 10.3109/08916939209148462

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  4 in total

1.  Thyroid eye disease.

Authors:  D Munro
Journal:  BMJ       Date:  1993-03-27

2.  IgA autoantibodies against human eye muscle antigen detected by western blotting and immunohistochemical methods in Graves' disease.

Authors:  I Molnár; V Kaczur; A Boros; G Krajczár; C Balázs
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

3.  Antibody-dependent cell-mediated cytotoxicity against orbital target cells in thyroid-associated ophthalmopathy and related disorders; close relationship between serum cytotoxic antibodies and parameters of eye muscle dysfunction.

Authors:  A Barsouk; K A Peele; J Kiljanski; C Stolarski; V Nebes; J S Kennerdell; R Volpe; J R Wall
Journal:  J Endocrinol Invest       Date:  1996-06       Impact factor: 4.256

4.  Color Doppler imaging of the superior ophthalmic vein in different clinical forms of Graves' orbitopathy.

Authors:  Mário L R Monteiro; Hélio Angotti-Neto; Joseph E Benabou; Alberto J Betinjane
Journal:  Jpn J Ophthalmol       Date:  2008-12-17       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.